EpiEndo
Reykjavik, IS · 1 known investors
EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for chronic respiratory diseases such as COPD, based on research into macrolides and their effects on the lung epithelium. Its lead program, EP395 (glasmacinal), is a non-antibacterial macrolide with anti-inflammatory activity that is Phase 2b ready.
Investors · 1
Frequently asked questions
- What does EpiEndo do?
- EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for chronic respiratory diseases such as COPD, based on research into macrolides and their effects on the lung epithelium. Its lead program, EP395 (glasmacinal), is a non-antibacterial macrolide with anti-inflammatory activity that is Phase 2b ready.
- Who are EpiEndo's investors?
- EpiEndo's investors include Brunnur Ventures GP.
- Where is EpiEndo headquartered?
- EpiEndo is headquartered in Reykjavik, IS.